PT - JOURNAL ARTICLE AU - Georgios Voloudakis AU - Gabriel Hoffman AU - Sanan Venkatesh AU - Kyung Min Lee AU - Kristina Dobrindt AU - James M. Vicari AU - Wen Zhang AU - Noam D. Beckmann AU - Shan Jiang AU - Daisy Hoagland AU - Jiantao Bian AU - Lina Gao AU - André Corvelo AU - Kelly Cho AU - Jennifer S. Lee AU - Sudha K. Iyengar AU - Shiuh-Wen Luoh AU - Schahram Akbarian AU - Robert Striker AU - Themistocles L. Assimes AU - Eric E. Schadt AU - Miriam Merad AU - Benjamin R. tenOever AU - Alexander W. Charney AU - Mount Sinai COVID-19 Biobank AU - VA Million Veteran Program COVID-19 Science Initiative AU - Kristen J. Brennand AU - Julie A. Lynch AU - John F. Fullard AU - Panos Roussos TI - IL10RB as a key regulator of COVID-19 host susceptibility and severity AID - 10.1101/2021.05.31.21254851 DP - 2021 Jan 01 TA - medRxiv PG - 2021.05.31.21254851 4099 - http://medrxiv.org/content/early/2021/06/02/2021.05.31.21254851.short 4100 - http://medrxiv.org/content/early/2021/06/02/2021.05.31.21254851.full AB - Background Recent efforts have identified genetic loci that are associated with coronavirus disease 2019 (COVID-19) infection rates and disease outcome severity. Translating these genetic findings into druggable genes and readily available compounds that reduce COVID-19 host susceptibility is a critical next step.Methods We integrate COVID-19 genetic susceptibility variants, multi-tissue genetically regulated gene expression (GReX) and perturbargen signatures to identify candidate genes and compounds that reverse the predicted gene expression dysregulation associated with COVID-19 susceptibility. The top candidate gene is validated by testing both its GReX and observed blood transcriptome association with COVID-19 severity, as well as by in vitro perturbation to quantify effects on viral load and molecular pathway dysregulation. We validate the in silico drug repositioning analysis by examining whether the top candidate compounds decrease COVID-19 incidence based on epidemiological evidence.Results We identify IL10RB as the top key regulator of COVID-19 host susceptibility. Predicted GReX up-regulation of IL10RB and higher IL10RB expression in COVID-19 patient blood is associated with worse COVID-19 outcomes. In vitro IL10RB overexpression is associated with increased viral load and activation of immune-related molecular pathways. Azathioprine and retinol are prioritized as candidate compounds to reduce the likelihood of testing positive for COVID-19.Conclusions We establish an integrative data-driven approach for gene target prioritization. We identify and validate IL10RB as a suitable molecular target for modulation of COVID-19 host susceptibility. Finally, we provide evidence for a few readily available medications that would warrant further investigation as drug repositioning candidates.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis research is based on data from the Million Veteran Program, Office of Research and Development, Veterans Health Administration, and was supported by award #MVP035. This publication does not represent the views of the Department of Veteran Affairs or the United States Government. This study was also supported by the National Institutes of Health (NIH), Bethesda, MD under award numbers K08MH122911 (Georgios Voloudakis), R01AG050986, R01AG065582, R01AG067025, U01MH116442, R01MH109677 (Panos Roussos), and by the Veterans Affairs Merit grants BX002395 and BX004189 (Panos Roussos). This study has also been funded in part by the Brain & Behavior Research Foundation via the 2020 NARSAD Young Investigator Grant #29350 (Georgios Voloudakis) and the Icahn School of Medicine at Mount Sinai via a COVID-19 Pilot Grant (Schahram Akbarian, Benjamin R. tenOever, Kristen J. Brennand).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:GReX analysis in MVP: These analyses were conducted under the protocol VA Million Veteran Program COVID-19 Science Initiative, which was approved by the Veterans Affairs Central Institutional Review Board and by the Research & Development Committee at the James J. Peters VA Medical Center.Gene expression profiling and EHR-based phenotyping in the Mount Sinai COVID-19 Biobank: This study was approved by the Institutional Review Board (IRB) at the Icahn School of Medicine at Mount Sinai (20-0327).Population-level analysis of the effect of compound and compound category use against COVID-19 incidence: Analysis of national VA data was conducted under the protocol, Leveraging Electronic Health Information to Advance Precision Medicine (LEAP), which was approved by VA Central Institutional Review Board and by the Research & Development Committees at Palo Alto, Salt Lake City, and West Haven VA Medical Centers.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data will be made available